Ariana Pelosci
Editor at Cancer Network
Editor @cancernetwrk | University of Delaware ‘21 | Author of Roxy and Velvet’s Big Adventure
Articles
-
1 week ago |
cancernetwork.com | Ariana Pelosci
The improvement of time to initial breast cancer treatment for patients classified as vulnerable was noted in safety net hospitals where the implementation of a multidisciplinary breast cancer clinic (MBCC) occurred, according to a press conference presentation from the 26th Annual Meeting of the American Society of Breast Surgeons. In the MBCC group, the time to first appointment was 11.3 days ± 10.1 vs 12.7 days ± 14.5 in the non-MBCC group (P = .21).
-
2 weeks ago |
cancernetwork.com | Ariana Pelosci
Endocrine therapy for 90 days prior to surgery and radiation therapy saw increased preference among patients and surgeons while allowing for an additional method to inform adjuvant therapy decisions, according to findings from the phase 2 POWER trial (NCT04272801) presented at a press briefing for the 26th Annual Meeting of American Society of Breast Surgeons.
-
2 weeks ago |
targetedonc.com | Ariana Pelosci
Radical prostatectomy was associated with lesser toxicity compared with combination modalities in patients with prostate cancer undergoing localized therapy, according to results presented at the 2025 American Urological Association Annual Meeting. Of the 47,387 patients enrolled, 39.7% experienced a genitourinary complication during the specific period. The most common included urinary incontinence (11.7%), kidney failure (8.8%), bladder disorder (2.9%), and cystitis (2.3%).
-
2 weeks ago |
cancernetwork.com | Ariana Pelosci
Patients with bladder cancer undergoing a radical cystectomy did not have worse survival when they had lymph node metastases staged with 18F-FDG PET/CT scans, according to a study presented at the 2025 American Urological Association Annual Meeting. The investigators aimed to compare the survival outcomes of patients who received 18F-FDG PET/CT who were staged and undergoing radical cystectomy with their clinical (cN) and pathological (pN) lymph node metastasis status.
-
2 weeks ago |
cancernetwork.com | Ariana Pelosci
Superior efficacy was noted with nurulimab plus prolgolimab vs prolgolimab alone as first-line treatment for patients with unresectable or metastatic melanoma, according to results from the phase 3 OCTAVA trial (NCT05732805) presented at the 2025 American Association for Clinical Research Annual Meeting.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 42
- Tweets
- 91
- DMs Open
- No
RT @ginacolumbusonc: Great time in the Big Apple with some of our @OncLive and @CancerNetwrk crew at @gotoPER #NYGU today. Awesome work! 🙌🏻…
It was great speaking with Dr. Taplin today during #NYGU! Excited to see CancerNetwork’s Women in Oncology program come together.
It was a happy #InternationalWomensDay — we sat down with Dr Mary-Ellen Taplin of @DanaFarber to discuss her career in GU oncology! Keep your eye out for a brand new #womeninonc program 👀 #NYGU @gotoPER @APelosci #pcsm https://t.co/uvbciyxGiC
It was great speaking with Dr. Gong about the upcoming @myESMO meeting. He gave a great overview on upcoming presentations, and which will be most impactful in the bladder and gastrointestinal space.
Thank you @CancerNetwrk @APelosci! Always a pleasure catching up on latest GI/GU cancer breakthroughs especially with an exciting @myESMO 2023 fast approaching @CSCancerCenter @CedarsSinaiMed @CedarsSinai